Results 181 to 190 of about 145,951 (305)

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

B Lymphocytes, but Not Dendritic Cells, Efficiently HIV-1 Trans Infect Naive CD4⁺ T Cells: Implications for the Viral Reservoir. [PDF]

mBio, 2021
Gerberick A, DeLucia DC, Piazza P, Alaoui-El-Azher M, Rinaldo CR, Sluis-Cremer N, Rappocciolo G.   +6 more
europepmc   +1 more source

Immunometabolic and Spatiotemporal Control of Tissue‐Resident Memory T Cell Biology

Barrier Immunity, EarlyView.
Tissue‐resident memory T (TRM) cells in barrier tissues provide a frontline defense against invading pathogens. Immune (Signals 1–3) and nutrient (Signal 4) cues play an integral role in directing TRM formation and heterogeneity. The spatial and temporal organization of these signals establishes durable TRM cells across tissues, enabling diverse ...
Jana L. Raynor, Hongbo Chi
wiley   +1 more source

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. [PDF]

Elife
Fombellida-Lopez C, Valaitienė A, Winchester L, Maes N, Dellot P, Vanwinge C, Ladang A, Cavalier E, Susin F, Vaira D, Hayette MP, Reenaers C, Moutschen M, Fletcher CV, Pasternak AO, Darcis G.   +15 more
europepmc   +1 more source

Nanoparticles in microdroplets: Recent advances in microfluidic generators for producing functional microbeads

Droplet, EarlyView.
Functional hybrid microbeads with electrical, magnetic, and/or optical responsiveness have emerged as versatile platforms for biotechnology. This review highlights recent advances in microfluidic technologies for producing such microbeads, with a focus on incorporating functional nanoparticles in microdroplet systems.
  Bayinqiaoge, Chengchen Zhang, Shi‐Yang Tang   +2 more
wiley   +1 more source

Viral reservoir characteristics in lymphoid tissues of HIV-1 elite controllers. [PDF]

JCI Insight
Marzi SK, Naasz CM, Carrere L, Capote CG, Roseto IC, Gao C, Cavassini M, Mastrangelo A, Lichterfeld M, Perreau M, Yu XG.   +10 more
europepmc   +1 more source

When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy

Exploration, EarlyView.
In the precision‐medicine era, rare diseases must not be sidelined in translational infrastructure. The Mr. Cai Lei—led “Ice‐Breaking Team” turns an amyotrophic lateral sclerosis patient community into a sustainable ecosystem, realigning philanthropy, data, and research and development to reshape rare‐disease pipelines and guide precision therapies ...
Yang Liu, Xue Xia, Yingfang Chen, Haoying Yang, Xiaochen Chen, Lei Cai, Bingyang Shi   +6 more
wiley   +1 more source

Adipose Tissue in SARS-CoV-2 Viral Tropism, Viral Replication, and the Concept of a Viral Reservoir: An Update. [PDF]

Obesity (Silver Spring)
Maher LC, Ryan PM, Caplice NM.
europepmc   +1 more source

Microengineering the Liver: Strategies for Constructing Functional Liver‐on‐a‐Chip Devices

Exploration, EarlyView.
This review summarizes recent advances in liver‐on‐a‐chip (LOC) technologies, including fabrication strategies and functional integration approaches, and discusses their promising applications in drug screening and related biomedical fields. ABSTRACT Reliable in vitro liver models are indispensable for researching liver diseases and developing ...
Jie Wang, Ziwei Liang, Jiapu Wang, Zongyi Li, Shaojie Wang, Yan Wei, Xin Xie, Di Huang   +7 more
wiley   +1 more source

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir. [PDF]

Elife
van Paassen PM, Pasternak AO, Bolluyt DC, van Dort KA, van Nuenen AC, Maurer I, Boeser-Nunnink B, Buchholtz NVEJ, Mahmoudi T, Lungu C, van Crevel R, Rokx C, Symons J, Nijhuis M, van der Veen ALIP, Vogt L, Klouwens MJ, Prins JM, Kootstra NA, de Bree GJ.   +19 more
europepmc   +1 more source